Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

Boehringer Ingelheim’s approach in CNS focuses on research to address unanswered challenges and needs in this area. With symptom led research we are investigating the underlying neurobiology of the brain across mental disorders such as schizophrenia, Alzheimer’s disease and depression.

We are optimistic that our symptom led approach, through better understanding of brain circuitry, will lead to the development of effective treatments that can be applied across a range of mental illness.

To complement our own innovation, we partner with academic and clinical experts, companies and research organisations at the forefront of neuroscience and psychiatry. One latest example is our collaboration with the Californian pharmaceutical company Arena. We are keen to explore opportunities to broaden research potential with the wider research community.